Genetic alteration of endothelial heparan sulfate selectively inhibits tumor angiogenesis

被引:98
作者
Fuster, Mark M.
Wang, Lianchun
Castagnola, Janice
Sikora, Lyudmila
Reddi, Krisanavane
Lee, Phillip H. A.
Radek, Katherine A.
Schuksz, Manuela
Bishop, Joseph R.
Gallo, Richard L.
Sriramarao, P.
Esko, Jeffrey D. [1 ]
机构
[1] Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA
[2] Univ Calif San Diego, Dept Med, Div Pulm & Crit Care Med, La Jolla, CA 92093 USA
[3] Univ Calif San Diego, Div Dermatol, La Jolla, CA 92093 USA
[4] La Jolla Inst Mol Med, Div Vasc Biol, San Diego, CA 92121 USA
[5] Vet Adm Med Ctr, La Jolla, CA 92161 USA
关键词
D O I
10.1083/jcb.200610086
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
To examine the role of endothelin heparan sulfate during angiogenesis, we generated mice bearing an endothelial-targeted deletion in the biosynthetic enzyme N-acetylglucosamine N-deacetylase/N-sulfotransferase 1 (Ndst1). Physiological angiogenesis during cutaneous wound repair was unaffected, as was growth and reproductive capacity of the mice. In contrast, pathological angiogenesis in experimental tumors was altered, resulting in smaller tumors and reduced microvascular density and branching. To simulate the angiogenic environment of the tumor, endothelial cells were isolated and propagated in vitro with proangiogenic growth factors. Binding of FGF-2 and VEGF(164) to cells and to purified heparan sulfate was dramatically reduced. Mutant endothelial cells also exhibited altered sprouting responses to FGF-2 and VEGF(164), reduced Erk phosphorylation, and an increase in apoptosis in branching assays. Corresponding changes in growth factor binding to tumor endothelium and apoptosis were also observed in vivo. These findings demonstrate a cell-autonomous effect of heparan sulfate on endothelial cell growth in the context of tumor angiogenesis.
引用
收藏
页码:539 / 549
页数:11
相关论文
共 71 条
[1]   Chinese hamster ovary cell mutants defective in glycosaminoglycan assembly and glucuronosyltransferase I [J].
Bai, XM ;
Wei, G ;
Sinha, A ;
Esko, JD .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (19) :13017-13024
[2]  
BAME KJ, 1989, J BIOL CHEM, V264, P8059
[3]   Update on clinical trials targeting vascular endothelial growth factor in cancer [J].
Bergsland, EK .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2004, 61 (21) :S12-S20
[4]   Matrix revolutions: 'tails' of basement-membrane components with angiostatic functions [J].
Bix, G ;
Iozzo, RV .
TRENDS IN CELL BIOLOGY, 2005, 15 (01) :52-60
[5]   Heparan sulfate proteoglycans and cancer [J].
Blackhall, FH ;
Merry, CLR ;
Davies, EJ ;
Jayson, GC .
BRITISH JOURNAL OF CANCER, 2001, 85 (08) :1094-1098
[6]  
Borgstrom P, 1996, CANCER RES, V56, P4032
[7]   VEGF-VEGF receptor complexes as markers of tumor vascular endothelium [J].
Brekken, RA ;
Thorpe, PE .
JOURNAL OF CONTROLLED RELEASE, 2001, 74 (1-3) :173-181
[8]  
Brekken RA, 1998, CANCER RES, V58, P1952
[9]   Angiogenesis in cancer and other diseases [J].
Carmeliet, P ;
Jain, RK .
NATURE, 2000, 407 (6801) :249-257
[10]   Characterization of a novel EGFP reporter mouse to monitor Cre recombination as demonstrated by a Tie2 Cre mouse line [J].
Constien, R ;
Forde, A ;
Liliensiek, B ;
Gröne, HJ ;
Nawroth, P ;
Hämmerling, G ;
Arnold, B .
GENESIS, 2001, 30 (01) :36-44